Hydroxamic Acid Hybrids for Lung Cancer Therapy

Area of Science:

• Oncology
• Medicinal Chemistry
• Epigenetics

Background:

• Lung cancer remains a leading cause of cancer-related deaths globally, with chemotherapy facing limitations like side effects and drug resistance.
• Histone deacetylase (HDAC) inhibitors offer a therapeutic strategy by reactivating silenced tumor-suppressor genes through epigenetic modulation.
• Hydroxamic acid hybrids have emerged as potent HDAC inhibitors with demonstrated efficacy against various cancer types.

Purpose of the Study:

• To review recent advancements (since 2020) in hydroxamic acid hybrids for anti-lung cancer applications.
• To summarize the structure-activity relationships of these novel compounds.
• To discuss their mechanisms of action in preclinical models.

Main Methods:

• Literature review focusing on studies published from 2020 onwards.
• Analysis of structure-activity relationships (SAR) of identified hydroxamic acid hybrids.
• Discussion of reported in vitro and in vivo experimental data.

Main Results:

• Hydroxamic acid hybrids demonstrate significant in vitro and in vivo efficacy against both drug-sensitive and drug-resistant lung cancer models.
• Specific structural modifications correlate with enhanced potency and selectivity.
• These compounds effectively inhibit HDAC activity, leading to anti-proliferative effects.

Conclusions:

• Hydroxamic acid hybrids represent a promising class of agents for developing innovative lung cancer therapies.
• Their ability to overcome drug resistance makes them particularly valuable.
• Further research into SAR and mechanisms can guide the development of next-generation anti-lung cancer drugs.